DOCSLIB.ORG

Tuberculosis Drug Discovery and Development 2019 Development and Discovery Drug  Tuberculosis • Giovanna Riccardi and Claudia Sala and Riccardi • Giovanna

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tuberculosis Drug Discovery and Development 2019 Development and Discovery Drug  Tuberculosis • Giovanna Riccardi and Claudia Sala and Riccardi • Giovanna Tuberculosis Drug Discovery and Development 2019 • Giovanna Riccardi and Sala Claudia Tuberculosis Drug Discovery and Development 2019 Edited by Giovanna Riccardi and Claudia Sala Printed Edition of the Special Issue Published in Applied Sciences www.mdpi.com/journal/applsci Tuberculosis Drug Discovery and Development 2019 Tuberculosis Drug Discovery and Development 2019 Editors Giovanna Riccardi Claudia Sala MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin Editors Giovanna Riccardi Claudia Sala Universita` degli Studi di Pavia Fondazione Toscana Life Sciences Italy Italy Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Applied Sciences (ISSN 2076-3417) (available at: https://www.mdpi.com/journal/applsci/special issues/Tuberculosis Drug Discovery). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03943-236-3 (Hbk) ISBN 978-3-03943-237-0 (PDF) c 2020 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Editors .............................................. vii Claudia Sala, Laurent Roberto Chiarelli and Giovanna Riccardi Editorial on Special Issue “Tuberculosis Drug Discovery and Development 2019” Reprinted from: Appl. Sci. 2020, 10, 6069, doi:10.3390/app10176069 ................. 1 Balachandra Bandodkar, Radha Krishan Shandil, Jagadeesh Bhat and Tanjore S. Balganesh Two Decades of TB Drug Discovery Efforts—What Have We Learned? Reprinted from: Appl. Sci. , 10, 5704, doi:10.3390/app10165704 .................... 5 Christian Lienhardt and Mario C. Raviglione TB Elimination Requires Discovery and Development of Transformational Agents Reprinted from: Appl. Sci. 2020, 10, 2605, doi:10.3390/app10072605 ................. 25 Angelo Iacobino, Lanfranco Fattorini and Federico Giannoni Drug-Resistant Tuberculosis 2020: Where We Stand Reprinted from: Appl. Sci. 2020, 10, 2153, doi:10.3390/app10062153 ................. 31 Paolo Mazzarello A Physical Cure for Tuberculosis: Carlo Forlanini and the Invention of Therapeutic Pneumothorax Reprinted from: Appl. Sci. 2020, 10, 3138, doi:10.3390/app10093138 ................. 49 Catherine Vilch`eze Mycobacterial Cell Wall: A Source of Successful Targets for Old and New Drugs Reprinted from: Appl. Sci. 2020, 10, 2278, doi:10.3390/app10072278 ................. 59 Giulia Degiacomi, Juan Manuel Belardinelli, Maria Rosalia Pasca, Edda De Rossi, Giovanna Riccardi and Laurent Roberto Chiarelli Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3 Reprinted from: Appl. Sci. 2020, 10, 623, doi:10.3390/app10020623 .................. 95 Vadim Makarov and Katar´ına Mikuˇsov´a Development of Macozinone for TB treatment: An Update Reprinted from: Appl. Sci. 2020, 10, 2269, doi:10.3390/app10072269 .................115 Caroline Shi-Yan Foo, Kevin Pethe and Andr´eanne Lupien Oxidative Phosphorylation—an Update on a New, Essential Target Space for Drug Discovery in Mycobacterium tuberculosis Reprinted from: Appl. Sci. 2020, 10, 2339, doi:10.3390/app10072339 .................127 Young Lag Cho and Jichan Jang Development of Delpazolid for the Treatment of Tuberculosis Reprinted from: Appl. Sci. 2020, 10, 2211, doi:10.3390/app10072211 .................161 Raphael Gries, Claudia Sala and Jan Rybniker Host-Directed Therapies and Anti-Virulence Compounds to Address Anti-Microbial Resistant Tuberculosis Infection Reprinted from: Appl. Sci. 2020, 10, 2688, doi:10.3390/app10082688 .................173 v Rob C. van Wijk, Rami Ayoun Alsoud, Hans Lennern¨as and Ulrika S. H. Simonsson Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations Reprinted from: Appl. Sci. 2020, 10, 2376, doi:10.3390/app10072376 .................191 Eduardo M. Bruch, St´ephanie Petrella and Marco Bellinzoni Structure-Based Drug Design for Tuberculosis: Challenges Still Ahead Reprinted from: Appl. Sci. 2020, 10, 4248, doi:10.3390/app10124248 .................211 Aaron Goff, Daire Cantillon, Leticia Muraro Wildner and Simon J Waddell Multi-Omics Technologies Applied to Tuberculosis Drug Discovery Reprinted from: Appl. Sci. 2020, 10, 4629, doi:10.3390/app10134629 .................231 Dina Visca, Simon Tiberi, Rosella Centis, Lia D’Ambrosio, Emanuele Pontali, Alessandro Wasum Mariani, Elisabetta Zampogna, Martin van den Boom, Antonio Spanevello and Giovanni Battista Migliori Post-Tuberculosis (TB) Treatment: The Role of Surgery and Rehabilitation Reprinted from: Appl. Sci. 2020, 10, 2734, doi:10.3390/app10082734 .................251 Rino Rappuoli Drugs and Vaccines Will Be Necessary to Control Tuberculosis Reprinted from: Appl. Sci. 2020, 10, 4026, doi:10.3390/app10114026 .................269 Carlos Martin, Nacho Aguilo, Dessislava Marinova and Jesus Gonzalo-Asensio Update on TB Vaccine Pipeline Reprinted from: Appl. Sci. 2020, 10, 2632, doi:10.3390/app10072632 .................271 vi Dedication “La tisi non le accorda che poche ore” From “La Traviata” by G. Verdi Dear readers I spent most of my life in the battle against Mycobacterium tuberculosis. My retirement is approaching and this special issue will conclude perfectly my TB research. I would like to dedicate it to Vita Quinci, one of the most positive student I had in my Lab, affected from Progressive Ossifying Fibrodysplasia, who suddenly died on May 1st. Her last message to me was: “Life is beautiful”. Giovanna Riccardi Vita Quinci: “La vita è bella” (life is beautiful) About the Editors Giovanna Riccardi 1976—Master Degree cum laude in Biology. 1977–1984—Fellowships aimed to work in Microbiology fields, at the Institute of Microbiology and Plant Physiology, University of Pavia; 1979—EMBO Short-Term fellowship, University of Liverpool (UK); 1984–1998—Researcher at the Department of Genetics and Microbiology, University of Pavia; 1999–2002—Associate Professor of Microbiology at the Department of Experimental, Environmental and Applied Biology, University of Genoa; Since October 2002—Full Professor of Microbiology, at the Department of Genetics and Microbiology (now Department of Biology and Biotechnology), University of Pavia; From January 2010 to December 2012—President of the SIMGBM (Italian Society of General Microbiology and Microbial Biotechnologies); Since August 2011—Member of the European Academy of Microbiology; The two main lines of research she is currently pursuing are: (1) RESISTANCE MECHANISMS AND TARGET IDENTIFICATION OF NEW DRUGS FOR Mycobacterium tuberculosis; (2) IDENTIFICATION OF NEW DRUGS AND NEW TARGETS FOR Burkholderia cenocepacia. FUNDING—Prof. G. Riccardi has obtained several grants from different sources: WHO; CNR-Bilateral Project; CNR-RAISA; MURST 40%; MURST-PRIN-1998, 2001, 2003, 2008; 2017; EC-V, VI and -VII frameworks; Istituto Superiore di Sanita,` Fondazione Fibrosi Cistica 2004, 2006, 2009, 2012, 2015. Cystic Fibrosis Foundation-USA 2017. Regarding the EC grants, she was always part of the steering committee. She is the author of several peer-reviewed articles, four book chapters, two International Patent Applications and several national and international communications. H-index Google Scholar: 42. Citations Google Scholar: 6099. Claudia Sala, PhD. Claudia Sala trained as a molecular microbiologist in the laboratory of Prof. Daniela Ghisotti, at the University of Milan (Italy), where she obtained her degree in Biological Sciences in 2000 and a PhD degree in Genetics and Molecular Biology in 2003. Her PhD thesis dealt with the transcriptional regulation of the furA and katG genes in mycobacteria in response to oxidative stress. In the framework of the EU FP6 ”New Medicines for Tuberculosis” (NM4TB) and FP7 “More Medicines for Tuberculosis” (MM4TB), she worked as a post-doctoral fellow in the laboratories of Prof. Stewart Cole, first at the Pasteur Institute in Paris, and then at the Ecole Polytechnique Fed´ erale´ de Lausanne, where she was subsequently promoted to senior scientist. She took active part in several research projects, including functional genomics and investigations on the M. tuberculosis Type VII Secretion System, and established the ChIP-Seq and RNA-Seq technologies in M. tuberculosis. She obtained the certificate of Biosafety Level 3 (BSL3) Safety Officer from the Swiss Confederation as well as the FESALA Category B and Category C licenses for performing and directing experiments involving animals. She was the recipient of the Swiss TB Award in 2010. She has recently moved to the Fondazione Toscana Life Sciences (TLS) in Siena, in the group led by Prof. Rino Rappuoli, and performs research on monoclonal antibodies and vaccine development. Her main interests include drug discovery against infectious diseases, vaccinology, host–pathogen interaction and biosafety. vii applied sciences Editorial Editorial on Special Issue “Tuberculosis Drug Discovery and Development 2019” Claudia Sala 1, Laurent Roberto Chiarelli
Load more

Recommended publications
  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K 38/08 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/031213 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 May 2015 (15.05.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/000,43 1 19 May 2014 (19.05.2014) US kind of regional protection available): ARIPO (BW, GH, 62/129,746 6 March 2015 (06.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicants : GELLER, Bruce, L.
    [Show full text]
  • Oxazolidinones for TB
    Oxazolidinones for TB: Current Status and Future Prospects 12th International Workshop on Clinical Pharmacology of Tuberculosis Drugs London, UK 10 September 2019 Lawrence Geiter, PhD Disclosures • Currently contract consultant with LegoChem Biosciences, Inc., Daejeon, Korea (LCB01-0371/delpazolid) • Previously employed with Otsuka Pharmaceutical Development and Commercialization, Inc. (delamanid, OPC-167832, LAM assay) What are Oxazolidinones • A family of antimicrobials mostly targeting an early step in protein synthesis • Cycloserine technically oxazolidinone but 2-oxazolidinone different MOA and chemical properties • New generation oxazolidinones bind to both 50S subunit and 30S subunit • Linezolid (Zyvox) and Tedizolid (Sivestro) approved for drug resistant skin infections and community acquired pneumonia Cycloserine • Activity against TB demonstrated in non- clinical and clinical studies • Mitochondrial toxicity >21 days limits use in TB treatment Linezolid Developing Oxazolidinones for TB Compound Generic Brand Sponsor Development Status TB Code- Activity/Trials PNU-100766 Linezolid Zyvox Pfizer Multiple regimen Yes/Yes TR-201 Tedizolid Sivextro Merck Pre-clinical efficacy Yes/No PNU-100480 Sutezolid Pfizer Multiple regimen studies Sequella Yes/Yes (PanACEA) TB Alliance LCB01-0371 Delpazolid LegoChem Bio EBA trial recruitment completed Yes/Yes TBI-223 - Global Alliance SAD trial launched Yes/Yes AZD5847 Posizolid AstraZenica Completed EBA Yes/No RX-1741 Radezolid Melinta IND for vaginal infections ?/No RBX-7644 Ranbezolid Rabbaxy None found ?/No MRX-4/MRX-1 Contezolid MicuRx Skin infections Yes/No U-100592 Eperezolid ? No clinical trials ?/No PK of Oxazolidinones in Development for TB Steady State PK Parameters Parameter Linezolid 600 Delpazolid 800 mg QD2 mg QD3 Cmax (mg/L) 17.8 8.9 Cmin (mg/L) 2.43 0.1 Tmax (h) 0.87 0.5 T1/2 (h) 3.54 1.7 AUC0-24 (µg*h/mL) 84.5 20.1 1 MIC90 (µg/mL) 0.25 0.5 References 1.
    [Show full text]
  • Comparative Analysis of Mutants in the Mycothiol Biosynthesis Pathway in Mycobacterium Smegmatis
    Biochemical and Biophysical Research Communications 363 (2007) 71–76 www.elsevier.com/locate/ybbrc Comparative analysis of mutants in the mycothiol biosynthesis pathway in Mycobacterium smegmatis Mamta Rawat a, Chantale Johnson a, Vanessa Cadiz a, Yossef Av-Gay b,* a Department of Biology, California State University-Fresno, Fresno, CA 937401, USA b Department of Medicine, Division of Infectious Diseases, University of British Columbia, Vancouver, BC, Canada V5Z 3J5 Received 17 August 2007 Available online 31 August 2007 Abstract The role of mycothiol in mycobacteria was examined by comparative analysis of mutants disrupted in the four known genes encoding the protein machinery needed for mycothiol biosynthesis. These mutants were sensitive to acid stress, antibiotic stress, alkylating stress, and oxidative stress indicating that mycothiol and mycothiol-dependent enzymes protect the mycobacterial cell against attack from various different types of stresses and toxic agents. Ó 2007 Elsevier Inc. All rights reserved. Keywords: Mycothiol; Mycothiol deacetylase; Mycothiol ligase; Mycothiol synthase; Oxidative stress; Toxins; Xenobiotics Mycobacteria, like most other Gram-positive bacteria do We have previously reported that Mycobacterium not make glutathione but produce another low molecular smegmatis mutants disrupted in the four known genes weight thiol, mycothiol (MSH) (Fig. 1), 1-D-myoinosityl- [3,9–11] involved in mycothiol biosynthesis are resistant to 2-(n-acetyl-L-cysteinyl)-amido-2-deoxy-a-D-glucopyranoside. isoniazid, a front-line drug used in the treatment of tubercu- Since MSH is unique to actinomycetales [1], enzymes losis. We have also reported that M. smegmatis mutants involved in MSH biosynthesis and metabolism are poten- lacking mycothiol ligase activity and thus mycothiol are tial targets for drugs directed against pathogenic mycobac- sensitive to a wide range of antibiotics, alkylating agents, teria like Mycobacterium tuberculosis.
    [Show full text]
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Great South African Molecules: the Case for Mycothiol
    REVIEW ARTICLE C.M. Nkambule, 67 S. Afr. J. Chem., 2017, 70, 67–81, <http://journals.sabinet.co.za/sajchem/>. Great South African Molecules: The Case For Mycothiol Comfort M. Nkambule Department of Chemistry, Tshwane University of Technology, Pretoria, 0001, South Africa. Received 13 September 2016, revised 15 March 2017, accepted 17 March 2017. ABSTRACT South Africa has one of the oldest chemical societies in the world and has a long history of natural products, synthetic, and medici- nal chemistry yet the visibility of molecules discovered or synthesized in South Africa is very low. Is this because South African scientists are incapable of discovering influential and celebrated molecules, or is there inadequate publicity of such discoveries? Perspective profiles on the discovery and scope of research on ‘Great South African Molecules’ should be a good start to redress this state of affairs. One such molecule deserving publicity is the antioxidant mycothiol which is produced by mycobacteria. This is a molecule of interest not only because of its medicinal potential in the fight against tuberculosis, but also from synthetic methodology and enzyme inhibition studies. This review aims to illuminate the scope of research in mycothiol chemistry for the purpose of promoting multidisciplinary investigations related to this South African molecule. KEYWORDS Mycothiol, Mycobacterium tuberculosis, great molecules, chemistry Nobel Prize. Table of Contents 1. What is a Great Molecule?· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 67 2. Is Mycothiol a Great Molecule? · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 71 2.1. Is Mycothiol a South African Molecule? · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 71 3. Why is Mycothiol a Molecule of Great Potential? · · · · · · · · · · · · · · · · · · · · · · · · · · · 72 3.1. Mycothiol’s Significance to the TB Problem· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · 72 3.2.
    [Show full text]
  • Improving Diagnostic Strategies for Latent Tuberculosis Infection in Populations at Risk for Developing Active Disease
    Improving diagnostic strategies for latent tuberculosis infection in populations at risk for developing active disease Laura Muñoz López Aquesta tesi doctoral està subjecta a la llicència Reconeixement 3.0. Espanya de Creative Commons. Esta tesis doctoral está sujeta a la licencia Reconocimiento 3.0. España de Creative Commons. This doctoral thesis is licensed under the Creative Commons Attribution 3.0. Spain License. UNIVERSIDAD DE BARCELONA Facultad de Medicina IMPROVING DIAGNOSTIC STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN POPULATIONS AT RISK FOR DEVELOPING ACTIVE DISEASE Memoria presentada por LAURA MUÑOZ LOPEZ Para optar al grado de Doctor en Medicina Barcelona, marzo de 2017 El Dr. Miguel Santín, proFesor asociado de la Facultad de Medicina de la Universidad de Barcelona y Médico Adjunto del Servicio de EnFermedades InFecciosas del Hospital Universitario de Bellvitge, hace constar que la tesis titulada “Improving diagnostic strategies For latent tuberculosis infection in populations at risk for developing active disease” que presenta la licenciada Laura Muñoz, ha sido realizada bajo su dirección en el campus de Bellvitge de la Facultad de Medicina, la considera Finalizada y autoriza su presentación para que sea deFendida ante el tribunal que corresponda. En Barcelona, marzo de 2017 Dr. Miguel Santín A mis padres A mi gran Familia The research presented in this thesis has been carried out thanks to the Fondo de Investigaciones Sanitarias Ministerio de Ciencia e Innovación Beca P-FIS 10/00443 AGRADECIMIENTOS Las primeras palabras de agradecimiento son sin duda para el director de esta tesis. Sin las ideas, horas de trabajo y paciencia de Miguel Santín ninguno de los estudios que componen esta tesis, ni por supuesto la propia tesis, hubiesen visto la luz.
    [Show full text]
  • Skin Probiotics ACCELERATING INNOVATION
    ACCELERATING INNOVATION James Madison University technologies are available for licensing through its nonprofit affiliate, James Madison Innovations, Inc. Skin Probiotics Inventors: Reid Harris and Kevin Minbiole Department: Biology and Chemistry Overview Research Funding and Source: National Science Foundation James Madison University inventors have filed a patent Years of Development: 4 years application on a helpful bacterium that could potentially be Technology Readiness: Research Development used as a therapy for human skin fungus such as athlete’s foot. Patent Status: U.S. patent pending 20110002891 The JMU inventors have developed a potential process to Contact: Mary Lou Bourne, Director of Technology Transfer deliver a helpful microbe, Janthinobacterium Lividum to the James Madison University skin using a pharmaceutically acceptable carrier. The microbe Phone: (540)568-2865 E-mail: [email protected] has been shown to suppress bacterial and fungal growth on animals and in lab demonstrations. Tech Transfer and Business Model Infections can be a problem for a wide array of hosts. For JMI is interested in identifying an existing company or example, there are a variety of infections, such as bacterial, entrepreneur interested in commercializing the technology viral and/or fungal infections, that affect a large percentage of either under an exclusive or a non-exclusive license. A the human population. Tricophyton rubrum, the fungus that small company or entrepreneur could further develop the causes athlete’s foot, is responsible for approximately 46% to technology, possibly using SBIR or STTR funding. 72% of cutaneous and nail mycoses worldwide. Onychomycosis, a common and persistent fungal infection, is Market and Competition In 2008, the U.S.
    [Show full text]
  • The Antimycobacterial Activity of Hypericum Perforatum Herb and the Effects of Surfactants
    Utah State University DigitalCommons@USU All Graduate Theses and Dissertations Graduate Studies 8-2012 The Antimycobacterial Activity of Hypericum perforatum Herb and the Effects of Surfactants Shujie Shen Utah State University Follow this and additional works at: https://digitalcommons.usu.edu/etd Part of the Engineering Commons Recommended Citation Shen, Shujie, "The Antimycobacterial Activity of Hypericum perforatum Herb and the Effects of Surfactants" (2012). All Graduate Theses and Dissertations. 1322. https://digitalcommons.usu.edu/etd/1322 This Thesis is brought to you for free and open access by the Graduate Studies at DigitalCommons@USU. It has been accepted for inclusion in All Graduate Theses and Dissertations by an authorized administrator of DigitalCommons@USU. For more information, please contact [email protected]. i THE ANTIMYCOBACTERIAL ACTIVITY OF HYPERICUM PERFORATUM HERB AND THE EFFECTS OF SURFACTANTS by Shujie Shen A thesis submitted in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in Biological Engineering Approved: Charles D. Miller, PhD Ronald C. Sims, PhD Major Professor Committee Member Marie K. Walsh, PhD Mark R. McLellan, PhD Committee Member Vice President for Research and Dean of the School of Graduate Studies UTAH STATE UNIVERSITY Logan, Utah 2012 ii Copyright © Shujie Shen 2012 All Rights Reserved iii ABSTRACT The Antimycobacterial Activity of Hypericum perforatum Herb and the Effects of Surfactants by Shujie Shen, Master of Science Utah State University, 2012 Major Professor: Dr. Charles D. Miller Department: Biological Engineering Due to the essential demands for novel anti-tuberculosis treatments for global tuberculosis control, this research investigated the antimycobacterial activity of Hypericum perforatum herb (commonly known as St.
    [Show full text]
  • Analysis of Mutations Leading to Para-Aminosalicylic Acid Resistance in Mycobacterium Tuberculosis
    www.nature.com/scientificreports OPEN Analysis of mutations leading to para-aminosalicylic acid resistance in Mycobacterium tuberculosis Received: 9 April 2019 Bharati Pandey1, Sonam Grover2, Jagdeep Kaur1 & Abhinav Grover3 Accepted: 31 July 2019 Thymidylate synthase A (ThyA) is the key enzyme involved in the folate pathway in Mycobacterium Published: xx xx xxxx tuberculosis. Mutation of key residues of ThyA enzyme which are involved in interaction with substrate 2′-deoxyuridine-5′-monophosphate (dUMP), cofactor 5,10-methylenetetrahydrofolate (MTHF), and catalytic site have caused para-aminosalicylic acid (PAS) resistance in TB patients. Focusing on R127L, L143P, C146R, L172P, A182P, and V261G mutations, including wild-type, we performed long molecular dynamics (MD) simulations in explicit solvent to investigate the molecular principles underlying PAS resistance due to missense mutations. We found that these mutations lead to (i) extensive changes in the dUMP and MTHF binding sites, (ii) weak interaction of ThyA enzyme with dUMP and MTHF by inducing conformational changes in the structure, (iii) loss of the hydrogen bond and other atomic interactions and (iv) enhanced movement of protein atoms indicated by principal component analysis (PCA). In this study, MD simulations framework has provided considerable insight into mutation induced conformational changes in the ThyA enzyme of Mycobacterium. Antimicrobial resistance (AMR) threatens the efective treatment of tuberculosis (TB) caused by the bacteria Mycobacterium tuberculosis (Mtb) and has become a serious threat to global public health1. In 2017, there were reports of 5,58000 new TB cases with resistance to rifampicin (frst line drug), of which 82% have developed multidrug-resistant tuberculosis (MDR-TB)2. AMR has been reported to be one of the top health threats globally, so there is an urgent need to proactively address the problem by identifying new drug targets and understanding the drug resistance mechanism3,4.
    [Show full text]
  • Revised Use-Function Classification (2007)
    INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY IPCS INTOX Data Management System (INTOX DMS) Revised Use-Function Classification (2007) The Use-Function Classification is used in two places in the INTOX Data Management System: the Communication Record and the Agent/Product Record. The two records are linked: if there is an agent record for a Centre Agent that is the subject of a call, the appropriate Intended Use-Function can be selected automatically in the Communication Record. The Use-Function Classification is used when generating reports, both standard and customized, and for searching the case and agent databases. In particular, INTOX standard reports use the top level headings of the Intended Use-Functions that were selected for Centre Agents in the Communication Record (e.g. if an agent was classified as an Analgesic for Human Use in the Communication Record, it would be logged as a Pharmaceutical for Human Use in the report). The Use-Function classification is very important for ensuring harmonized data collection. In version 4.4 of the software, 5 new additions were made to the top levels of the classification provided with the system for the classification of organisms (items XIV to XVIII). This is a 'convenience' classification to facilitate searching of the Communications database. A taxonomic classification for organisms is provided within the INTOX DMS Agent Explorer. In May/June 2006 INTOX users were surveyed to find out whether they had made any changes to the Use-Function Classification. These changes were then discussed at the 4th and 5th Meetings of INTOX Users. Version 4.5 of the INTOX DMS includes the revised pesticides classification (shown in full below).
    [Show full text]
  • Remedy and Elimination of Tuberculosis” Akanksha Mishra [email protected]
    The University of San Francisco USF Scholarship: a digital repository @ Gleeson Library | Geschke Center Master's Theses Theses, Dissertations, Capstones and Projects Winter 12-15-2017 A Novel Model of “Remedy and Elimination of Tuberculosis” Akanksha Mishra [email protected] Follow this and additional works at: https://repository.usfca.edu/thes Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Diseases Commons, Epidemiology Commons, International Public Health Commons, and the Other Medicine and Health Sciences Commons Recommended Citation Mishra, Akanksha, "A Novel Model of “Remedy and Elimination of Tuberculosis”" (2017). Master's Theses. 1118. https://repository.usfca.edu/thes/1118 This Thesis is brought to you for free and open access by the Theses, Dissertations, Capstones and Projects at USF Scholarship: a digital repository @ Gleeson Library | Geschke Center. It has been accepted for inclusion in Master's Theses by an authorized administrator of USF Scholarship: a digital repository @ Gleeson Library | Geschke Center. For more information, please contact [email protected]. A Novel Model of “Remedy and Elimination of Tuberculosis” By: Akanksha Mishra University of San Francisco November 21, 2017 MASTER OF ARTS in INTERNATIONAL STUDIES 1 ABSTRACT OF THE DISSERTATION A Novel Model of “Remedy and Elimination of Tuberculosis” MASTER OF ARTS in INTERNATIONAL STUDIES By AKANKSHA MISHRA December 18, 2017 UNIVERSITY OF SAN FRANCISCO Under the guidance and approval of the committee, and approval by all the members, this thesis project has been accepted in partial fulfillment of the requirements for the degree. Adviser__________________________________ Date ________________________ Academic Director Date ________________________________________ ______________________ 2 ABSTRACT Tuberculosis (TB), is one of the top ten causes of death worldwide.
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]